Skip to Main Content
DownloadHi-Res Photo

Jonathan Leventhal, MD

Assistant Professor of Dermatology; Associate Director of Residency Program, Dermatology; Director of Onco-Dermatology Clinic; Department of Dermatology

Contact Information

Jonathan Leventhal, MD

Mailing Address

  • Dermatology

    15 York Street, LMP 5040

    New Haven, CT 06510

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Leventhal's principal clinical research focus as a faculty member has been to investigate skin, hair and nail toxicities from cancer therapies. He has published in high impact journals and presented his work at national and international conferences (American Academy of Dermatology, World Congress of Dermatology). He serves as a Principal Investigator on several clinical trials studying rashes from new types of cancer therapies, and collaborates closely with medical oncologists, surgical oncologists and radiation oncologists as a sub-investigator on many trials at the Yale Cancer Center.

Extensive Research Description

dermatology toxicities; cutaneous immune-related adverse events

Coauthors

Research Interests

Drug Eruptions; Dermatology; Melanoma

Selected Publications

  • Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2019, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.
  • Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.
  • Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy.Mittal A, Mittal V, Panse G, Choi JN, Kwong BY, Leventhal JS. Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy. Journal Of The American Academy Of Dermatology 2019, 81: 260-262. PMID: 30797843, DOI: 10.1016/j.jaad.2019.02.039.
  • Hypersensitivity reactions to vaccine constituents: a case series and review of the literature.Leventhal JS, Berger EM, Brauer JA, Cohen DE. Hypersensitivity reactions to vaccine constituents: a case series and review of the literature. Dermatitis : Contact, Atopic, Occupational, Drug 2012, 23: 102-9. PMID: 22653170, DOI: 10.1097/DER.0b013e31825228cf.
  • Is it time to re-evaluate the treatment of pemphigus?Leventhal JS, Sanchez MR. Is it time to re-evaluate the treatment of pemphigus? Journal Of Drugs In Dermatology : JDD 2012, 11: 1200-6. PMID: 23134985.
  • Skin conditions of baseball, cricket, and softball players.Farhadian JA, Tlougan BE, Adams BB, Leventhal JS, Sanchez MR. Skin conditions of baseball, cricket, and softball players. Sports Medicine (Auckland, N.Z.) 2013, 43: 575-89. PMID: 23456491, DOI: 10.1007/s40279-013-0022-4.
  • Postoperative pathergic pyoderma gangrenosum after aortic aneurysm repair.Leventhal JS, Tlougan BE, Mandell JA, Friedman-Kien AE, Meehan SA. Postoperative pathergic pyoderma gangrenosum after aortic aneurysm repair. International Journal Of Dermatology 2013, 52: 1401-3. PMID: 24164156, DOI: 10.1111/j.1365-4632.2011.05198.x.
  • Crystal deodorant-induced axillary granulomatous dermatitis.Leventhal JS, Farhadian JA, Miller KE, Tlougan BE, Patel RR, Sanchez MR. Crystal deodorant-induced axillary granulomatous dermatitis. International Journal Of Dermatology 2014, 53: e59-60. PMID: 23621443, DOI: 10.1111/j.1365-4632.2012.05686.x.
  • 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. Journal Of The American Academy Of Dermatology 2015, 73: 645-54. PMID: 26259990, DOI: 10.1016/j.jaad.2015.06.060.
  • Purpuric Lesions on Acral Sites. Type I cryoglobulinemia associated with multiple myeloma.Fraser Gibson J, Leventhal JS, King B. Purpuric Lesions on Acral Sites. Type I cryoglobulinemia associated with multiple myeloma. JAMA Dermatology 2015, 151: 659-60. PMID: 25738282, DOI: 10.1001/jamadermatol.2014.5198.
  • Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream.Leventhal JS, Odell ID, Imaeda S, Maverakis E, King BA. Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream. JAAD Case Reports 2016, 2: 114-6. PMID: 27051847, PMCID: PMC4810288, DOI: 10.1016/j.jdcr.2016.01.004.
  • Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.
  • Skin manifestations of endocrine and neuroendocrine tumors.Leventhal JS, Braverman IM. Skin manifestations of endocrine and neuroendocrine tumors. Seminars In Oncology 2016, 43: 335-40. PMID: 27178685, DOI: 10.1053/j.seminoncol.2016.02.022.
  • Recurrent Coxsackievirus Infection in a Patient with Lamellar Ichthyosis.Damsky WE, Leventhal JS, Khalil D, Vesely MD, Craiglow BG, Milstone LM, Choate KA. Recurrent Coxsackievirus Infection in a Patient with Lamellar Ichthyosis. Pediatric Dermatology 2016, 33: e140-2. PMID: 26821985, PMCID: PMC7226923, DOI: 10.1111/pde.12769.
  • Radiation Dermatitis: Recognition, Prevention, and Management.Leventhal J, Young MR. Radiation Dermatitis: Recognition, Prevention, and Management. Oncology (Williston Park, N.Y.) 2017, 31: 885-7, 894-9. PMID: 29297172.
  • Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals Of Hematology 2017, 96: 1037-1039. PMID: 28220192, DOI: 10.1007/s00277-017-2954-5.
  • Purpuric lesions of the scalp, axillae, and groin of an infant.Khurana M, Leventhal JS, Levy L, McNiff JM, Antaya RJ. Purpuric lesions of the scalp, axillae, and groin of an infant. Cutis 2017, 99: 398;405;406. PMID: 28686757.
  • Gemcitabine-associated acute lipodermatosclerosislike eruption: An underrecognized phenomenon.Mittal A, Leventhal JS. Gemcitabine-associated acute lipodermatosclerosislike eruption: An underrecognized phenomenon. JAAD Case Reports 2017, 3: 190-195. PMID: 28443306, PMCID: PMC5394206, DOI: 10.1016/j.jdcr.2017.02.014.
  • The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies.Li AW, Yin ES, Stahl M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Reviews 2017, 31: 370-388. PMID: 28732587, DOI: 10.1016/j.blre.2017.07.003.
  • Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands.Ramachandran SM, Leventhal JS, Franco LG, Mir A, Walters RF, Franks AG. Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands. Lupus Science & Medicine 2017, 4: e000207. PMID: 28331627, PMCID: PMC5353283, DOI: 10.1136/lupus-2017-000207.
  • Ulcerative Plaques and Nodules on the Lower Extremity: A Quiz.Mittal A, Subtil A, Leventhal JS. Ulcerative Plaques and Nodules on the Lower Extremity: A Quiz. Acta Dermato-venereologica 2017, 97: 866-867. PMID: 28350040, DOI: 10.2340/00015555-2659.
  • Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab.Li AW, Ko CJ, Leventhal JS. Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab. European Journal Of Dermatology : EJD 2017, 27: 325-326. PMID: 28414193, DOI: 10.1684/ejd.2017.2989.
  • Cyanosis of the foot.Shi VJ, Leventhal JS, Mensah KA, Galan A, Choate KA. Cyanosis of the foot. Cutis 2017, 100: 206;209;210. PMID: 29136053.
  • A 54-year-old woman with arthritis and discoloration of the hands, ears, and sclerae.Yin ES, Knispel JD, McNiff JM, Leventhal JS. A 54-year-old woman with arthritis and discoloration of the hands, ears, and sclerae. International Journal Of Dermatology 2017, 56: 715-717. PMID: 27651033, DOI: 10.1111/ijd.13415.
  • Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding.Yin ES, Totonchy MB, Leventhal JS. Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding. JAAD Case Reports 2017, 3: 90-92. PMID: 28280766, PMCID: PMC5334519, DOI: 10.1016/j.jdcr.2016.10.008.
  • Hypertrophic Lichen Planus and Well-Differentiated Squamous Cell Carcinoma: A Diagnostic Conundrum.Totonchy MB, Leventhal JS, Ko CJ, Leffell DJ. Hypertrophic Lichen Planus and Well-Differentiated Squamous Cell Carcinoma: A Diagnostic Conundrum. Dermatologic Surgery : Official Publication For American Society For Dermatologic Surgery [et Al.] 2018, 44: 1466-1470. PMID: 29360655, DOI: 10.1097/DSS.0000000000001465.
  • Erythema Nodosum-like Eruption in the Setting of Sorafenib Therapy.Coleman EL, Cowper SE, Stein SM, Leventhal JS. Erythema Nodosum-like Eruption in the Setting of Sorafenib Therapy. JAMA Dermatology 2018, 154: 369-370. PMID: 29453869, DOI: 10.1001/jamadermatol.2017.5733.
  • A 71-year-old man with a hemorrhagic vesicular eruption.Hamilton CE, King BA, Cowper SE, Hochster H, Leventhal JS. A 71-year-old man with a hemorrhagic vesicular eruption. International Journal Of Dermatology 2018, 57: 147-148. PMID: 29057466, DOI: 10.1111/ijd.13793.
  • Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin.Coleman E, Panse G, Haldas J, Gettinger SN, Leventhal JS. Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin. JAAD Case Reports 2018, 4: 669-671. PMID: 30112450, PMCID: PMC6091308, DOI: 10.1016/j.jdcr.2018.06.022.
  • Lip ulceration in an immunocompromised patient.Mittal A, Leventhal JS. Lip ulceration in an immunocompromised patient. JAAD Case Reports 2018, 4: 214-216. PMID: 29527548, PMCID: PMC5842327, DOI: 10.1016/j.jdcr.2017.07.011.
  • Violaceous plaques and papulonodules on the umbilicus.Leventhal JS, Yin E, Imaeda S. Violaceous plaques and papulonodules on the umbilicus. Cutis 2018, 101: E11-E13. PMID: 29718029.
  • Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma.Turner N, Leventhal J. Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma. International Journal Of Dermatology 2018, 57: e90-e92. PMID: 30091457, DOI: 10.1111/ijd.14191.
  • Necrotic cheek ulcer in a liver transplant patient.Coleman E, Levy L, Panse G, Leventhal JS. Necrotic cheek ulcer in a liver transplant patient. International Journal Of Dermatology 2019, 58: 285-287. PMID: 29926899, PMCID: PMC6309531, DOI: 10.1111/ijd.14101.
  • Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors.Coleman E, Panse G, Cowper S, Lacy J, Leventhal J. Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors. JAAD Case Reports 2019, 5: 170-172. PMID: 30740499, PMCID: PMC6357547, DOI: 10.1016/j.jdcr.2018.11.021.
  • Multiple Lip Papules and Nodules in an Adult Man.Smith N, Glusac E, Leventhal J. Multiple Lip Papules and Nodules in an Adult Man. JAMA Dermatology 2019, 155: 485-486. PMID: 30840027, DOI: 10.1001/jamadermatol.2018.5240.
  • Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis.Atzmony L, Khan HM, Lim YH, Paller AS, Levinsohn JL, Holland KE, Mirza FN, Yin E, Ko CJ, Leventhal JS, Choate KA. Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis. JAMA Dermatology 2019, 155: 548-555. PMID: 30942823, PMCID: PMC6506890, DOI: 10.1001/jamadermatol.2019.0016.
  • Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2020, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.
  • B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For Immunotherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.
  • Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease.Coleman E, Panse G, Cowper S, Prebet T, Gore S, Leventhal J. Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. Journal Of Cutaneous Pathology 2019, 46: 930-934. PMID: 31254406, DOI: 10.1111/cup.13537.
  • Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy.Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, Choate KA. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. Journal Of The American Academy Of Dermatology 2020, 82: 123-131. PMID: 31449901, PMCID: PMC7039698, DOI: 10.1016/j.jaad.2019.08.043.
  • Successful management of malodor from fungating tumors using crushed metronidazole tablets.Hu JK, Ligtenberg KG, Leventhal J, Bunick CG. Successful management of malodor from fungating tumors using crushed metronidazole tablets. JAAD Case Reports 2020, 6: 26-29. PMID: 31909133, PMCID: PMC6938872, DOI: 10.1016/j.jdcr.2019.10.025.
  • Dermatologic conditions in women receiving systemic cancer therapy.Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. International Journal Of Women's Dermatology 2019, 5: 285-307. PMID: 31909148, PMCID: PMC6938835, DOI: 10.1016/j.ijwd.2019.10.003.
  • Tense Bullae and Pruritus.Vesely MD, Olamiju BA, Leventhal JS. Tense Bullae and Pruritus. American Family Physician 2020, 101: 305-306. PMID: 32109022, PMCID: PMC7255498.
  • The rash in life-threatening metabolic and endocrine disorders.Mirza FN, Leventhal JS. The rash in life-threatening metabolic and endocrine disorders. Clinics In Dermatology 2020, 38: 79-85. PMID: 32197751, DOI: 10.1016/j.clindermatol.2019.10.018.
  • The life-threatening eruptions of immune checkpoint inhibitor therapy.Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics In Dermatology 2020, 38: 94-104. PMID: 32197753, DOI: 10.1016/j.clindermatol.2019.10.015.
  • Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.Tattersall IW, Leventhal JS. Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist. The Yale Journal Of Biology And Medicine 2020, 93: 123-132. PMID: 32226342, PMCID: PMC7087048.
  • Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies.Olamiju B, Bhullar S, Coleman EL, Leventhal JS. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies. Journal Of The American Academy Of Dermatology 2021, 84: 806-808. PMID: 32526318, DOI: 10.1016/j.jaad.2020.06.010.
  • A rapidly growing, exophytic nodule on the chest.Ramseier JY, Cowper SE, Leventhal JS, Vesely MD. A rapidly growing, exophytic nodule on the chest. JAAD Case Reports 2020, 6: 417-419. PMID: 32382633, PMCID: PMC7200183, DOI: 10.1016/j.jdcr.2020.02.038.
  • Epidemiology, treatment, survival, and prognostic factors of cutaneous mucoepidermoid carcinoma: A distinct entity with an indolent clinical course.Mirza FN, Yumeen S, Zogg CK, Mirza HN, Leventhal JS. Epidemiology, treatment, survival, and prognostic factors of cutaneous mucoepidermoid carcinoma: A distinct entity with an indolent clinical course. Journal Of The American Academy Of Dermatology 2020, 83: 1827-1830. PMID: 32446830, PMCID: PMC7669598, DOI: 10.1016/j.jaad.2020.05.086.
  • Tender subcubcutaneous plaques in a patient with acute myeloid leukemia.Olamiju B, Myung P, Grant M, Leventhal JS. Tender subcubcutaneous plaques in a patient with acute myeloid leukemia. International Journal Of Dermatology 2021, 60: 311-313. PMID: 32424815, DOI: 10.1111/ijd.14943.
  • Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series.Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.
  • Association between halo nevi and melanoma in adults: A multicenter retrospective case series.Haynes D, Strunck JL, Said J, Tam I, Varedi A, Topham CA, Olamiju B, Wei BM, Erickson MK, Wang LL, Tan A, Stoner R, Hartman RI, Lilly E, Grossman D, Curtis JA, Westerdahl JS, Leventhal JS, Choi JN, Chu EY, Ming ME, Stein JA, Liebman TN, Berry E, Greiling TM. Association between halo nevi and melanoma in adults: A multicenter retrospective case series. Journal Of The American Academy Of Dermatology 2021, 84: 1164-1166. PMID: 32822787, DOI: 10.1016/j.jaad.2020.08.056.
  • Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou-Alfa G. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. The Oncologist 2021, 26: e316-e326. PMID: 33021006, PMCID: PMC7873330, DOI: 10.1002/onco.13552.
  • Skin puckering and edema during durvalumab therapy.Olamiju B, Odell I, Panse G, Eder JP, Leventhal JS. Skin puckering and edema during durvalumab therapy. JAAD Case Reports 2021, 7: 110-112. PMID: 33364282, PMCID: PMC7750709, DOI: 10.1016/j.jdcr.2020.11.019.
  • Cutaneous immune-related adverse events to checkpoint inhibitors.Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.
  • Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy.Singh K, Wang A, Heald P, McNiff JM, Suozzi K, King B, Leventhal J, Damsky W. Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. JAAD Case Reports 2021, 7: 122-124. PMID: 33426249, PMCID: PMC7777455, DOI: 10.1016/j.jdcr.2020.11.016.
  • Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).Coleman EL, Olamiju B, Leventhal JS. Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). Oncology Reports 2021, 45: 891-898. PMID: 33650659, PMCID: PMC7859912, DOI: 10.3892/or.2020.7911.
  • Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma.Pach J, Olamiju B, Weiss S, Damsky W, Leventhal J. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma. JAMA Dermatology 2021, 157: 468-469. PMID: 33688919, DOI: 10.1001/jamadermatol.2021.0058.
  • Dermatologic toxicities associated with radiation therapy in women with breast cancer.Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. International Journal Of Women's Dermatology 2020, 6: 349-356. PMID: 33898697, PMCID: PMC8060663, DOI: 10.1016/j.ijwd.2020.07.015.
  • Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer.Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.
  • Erythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event.Pach J, Moody K, Ring N, Panse G, Zhang M, Deverapalli S, Leventhal J. Erythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event. JAAD Case Reports 2021, 13: 118-120. PMID: 34189226, PMCID: PMC8220292, DOI: 10.1016/j.jdcr.2021.05.002.
  • US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm.Lacouture ME, Choi J, Ho A, Leventhal J, McLellan BN, Andriessen A, Sauder MB, Mitchell E. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm. Journal Of Drugs In Dermatology : JDD 2021, 20: 3ss-s19. PMID: 34491030, DOI: 10.36849/jdd.6229.
  • Iatrogenic calcinosis cutis from extravasated phosphate-containing solution treated with topical sodium thiosulfate.Xie CB, Kidacki M, Ring N, Panse G, Leventhal JS. Iatrogenic calcinosis cutis from extravasated phosphate-containing solution treated with topical sodium thiosulfate. JAAD Case Reports 2021, 17: 31-33. PMID: 34692964, PMCID: PMC8517711, DOI: 10.1016/j.jdcr.2021.09.013.
  • Bullous Pemphigoid Exacerbated by Radiation Therapy: An Atypical Presentation.Choi R, Cowper S, Young M, Leventhal J. Bullous Pemphigoid Exacerbated by Radiation Therapy: An Atypical Presentation. Advances In Radiation Oncology 2022, 7: 100794. PMID: 34984247, PMCID: PMC8693003, DOI: 10.1016/j.adro.2021.100794.

Clinical Trials

ConditionsStudy Title
Other SkinA Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Edit Profile